Literature DB >> 25896551

Pituitary function and morphology in Fabry disease.

Luigi Maione1, Fabio Tortora2, Roberta Modica3, Valeria Ramundo3, Eleonora Riccio4, Aurora Daniele5, Maria Paola Belfiore2, Annamaria Colao3, Antonio Pisani4, Antongiulio Faggiano6.   

Abstract

Endocrine abnormalities are known to affect patients with Fabry disease (FD). Pituitary gland theoretically represents an ideal target for FD because of high vascularization and low proliferation rate. We explored pituitary morphology and function in a cohort of FD patients through a prospectic, monocentric study at an Academic Tertiary Center. The study population included 28 FD patients and 42 sex and age-matched normal subjects. The protocol included a contrast enhancement pituitary MRI, the assessment of pituitary hormones, anti-pituitary, and anti-hypothalamus antibodies. At pituitary MRI, an empty sella was found in 11 (39%) FD patients, and in 2 (5%) controls (p < 0.001). Pituitary volume was significantly smaller in FD than in controls (p < 0.001). Determinants of pituitary volume were age and alpha-galactosidase enzyme activity. Both parameters resulted independently correlated at multivariate analysis. Pituitary function was substantially preserved in FD patients. Empty sella is a common finding in patients with FD. The major prevalence in the elderly supports the hypothesis of a progressive pituitary shrinkage overtime. Pituitary function seems not to be impaired in FD. An endocrine workup with pituitary hormone assessment should be periodically performed in FD patients, who are already at risk of cardiovascular complications.

Entities:  

Keywords:  Diencephalic MRI; Empty sella; Fabry disease; Pituitary

Mesh:

Year:  2015        PMID: 25896551     DOI: 10.1007/s12020-015-0604-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  22 in total

1.  Blood flow in portal systems with special reference to the rat pituitary gland.

Authors:  P D Lees; D T Lynch; H K Richards; A H Lovick; S Perry; J D Pickard
Journal:  J Cereb Blood Flow Metab       Date:  1992-01       Impact factor: 6.200

2.  Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody.

Authors:  K Thapar; K Kovacs; B W Scheithauer; L Stefaneanu; E Horvath; P J Pernicone; D Murray; E R Laws
Journal:  Neurosurgery       Date:  1996-01       Impact factor: 4.654

3.  Alteration of the growth hormone axis, visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the visceral adiposity index.

Authors:  Carolina Di Somma; Alessandro Ciresi; Marco C Amato; Silvia Savastano; Maria Cristina Savanelli; Elisabetta Scarano; Annamaria Colao; Carla Giordano
Journal:  Endocrine       Date:  2014-11-09       Impact factor: 3.633

4.  Primary empty sella.

Authors:  Laura De Marinis; Stefania Bonadonna; Antonio Bianchi; Giulio Maira; Andrea Giustina
Journal:  J Clin Endocrinol Metab       Date:  2005-06-21       Impact factor: 5.958

5.  Detection of antipituitary and antihypothalamus antibodies to investigate the role of pituitary or hypothalamic autoimmunity in patients with selective idiopathic hypopituitarism.

Authors:  Annamaria De Bellis; Elena Pane; Giuseppe Bellastella; Antonio A Sinisi; Caterina Colella; Roberta Giordano; Claudia Giavoli; Andrea Lania; Maria R Ambrosio; Carolina Di Somma; Maria C Zatelli; Emanuela Arvat; Annamaria Colao; Antonio Bizzarro; Antonio Bellastella
Journal:  Clin Endocrinol (Oxf)       Date:  2011-09       Impact factor: 3.478

6.  Testicular and epididymal involvement in Fabry's disease.

Authors:  M Nistal; R Paniagua; M L Picazo
Journal:  J Pathol       Date:  1983-10       Impact factor: 7.996

Review 7.  Pituitary tumours: inflammatory and granulomatous expansive lesions of the pituitary.

Authors:  R Carpinteri; I Patelli; F F Casanueva; A Giustina
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-10       Impact factor: 4.690

Review 8.  Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature.

Authors:  Antonio Pisani; Bianca Visciano; Graciana Diez Roux; Massimo Sabbatini; Caterina Porto; Giancarlo Parenti; Massimo Imbriaco
Journal:  Mol Genet Metab       Date:  2012-08-11       Impact factor: 4.797

Review 9.  Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy.

Authors:  Juan-Andres Rivera
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

Review 10.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

View more
  1 in total

1.  Endocrine disorders in patients with Fabry disease: insights from a reference centre prospective study.

Authors:  Christina Bothou; Felix Beuschlein; Albina Nowak
Journal:  Endocrine       Date:  2021-11-09       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.